Literature DB >> 21167844

Heterogeneous distribution of angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: vessel, organ and species specificity.

Roman Metzger1, Folker E Franke, Rainer M Bohle, François Alhenc-Gelas, Sergei M Danilov.   

Abstract

Angiotensin I-converting enzyme (kininase II, ACE, CD143) availability is a determinant of local angiotensin and kinin concentrations and physiological actions. Limited information is available on ACE synthesis in peripheral vascular beds. We studied the distribution of ACE along the human and rat vascular tree, and determined whether the enzyme was uniformly distributed in all endothelial cells (EC) or if differences occurred among vessels and organs. The distribution of ACE was assessed by using a panel of anti-human ACE monoclonal antibodies and serial sections of the entire vascular tree of humans. Comparison was made with other EC markers. EC of small muscular arteries and arterioles displayed high ACE immunoreactivity in all organs studied except the kidney, while EC of large arteries and of veins were poorly reactive or completely negative. Only 20% on average of capillary EC in each organ, including the heart, stained for ACE, with the remarkable exception of the lung and kidney. In the lung all capillary EC were labeled intensively for ACE, whereas in the kidney the entire vasculature was devoid of detectable enzyme. In contrast to the man, the rat showed homogeneous endothelial expression of ACE in all large and middle-sized arteries, and in veins, but in renal vessels ACE expression was reduced. This study documents a vessel, organ and species specific pattern of distribution of endothelial ACE. The markedly reduced ACE content of the renal vasculature may protect the renal circulation against excess angiotensin II formation and kinin depletion, and maintain high renal blood flow.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21167844     DOI: 10.1016/j.mvr.2010.12.003

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  27 in total

Review 1.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

2.  Acute, local infusion of angiotensin II impairs microvascular and metabolic insulin sensitivity in skeletal muscle.

Authors:  Dino Premilovac; Emily Attrill; Stephen Rattigan; Stephen M Richards; Jeonga Kim; Michelle A Keske
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

3.  ACE phenotyping in Gaucher disease.

Authors:  Sergei M Danilov; Victoria E Tikhomirova; Roman Metzger; Irina A Naperova; Tatiana M Bukina; Ozlem Goker-Alpan; Nahid Tayebi; Nurshat M Gayfullin; David E Schwartz; Larisa M Samokhodskaya; Olga A Kost; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2018-02-17       Impact factor: 4.797

Review 4.  Angiotensin-converting enzyme in innate and adaptive immunity.

Authors:  Kenneth E Bernstein; Zakir Khan; Jorge F Giani; Duo-Yao Cao; Ellen A Bernstein; Xiao Z Shen
Journal:  Nat Rev Nephrol       Date:  2018-03-26       Impact factor: 28.314

5.  Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension.

Authors:  Ian Morecroft; Katie White; Paola Caruso; Margaret Nilsen; Lynn Loughlin; Raul Alba; Paul N Reynolds; Sergei M Danilov; Andrew H Baker; Margaret R Maclean
Journal:  Mol Ther       Date:  2012-04-24       Impact factor: 11.454

6.  LPS-induced effects on angiotensin I-converting enzyme expression and shedding in human pulmonary microvascular endothelial cells.

Authors:  M I Hermanns; A M Müller; M Tsokos; C J Kirkpatrick
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-10-29       Impact factor: 2.416

Review 7.  Polarized Proteins in Endothelium and Their Contribution to Function.

Authors:  Abigail G Wolpe; Claire A Ruddiman; Phillip J Hall; Brant E Isakson
Journal:  J Vasc Res       Date:  2021-01-27       Impact factor: 1.934

8.  Conformational changes of blood ACE in chronic uremia.

Authors:  Maxim N Petrov; Valery Y Shilo; Alexandr V Tarasov; David E Schwartz; Joe G N Garcia; Olga A Kost; Sergei M Danilov
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

9.  A novel splice-site mutation in angiotensin I-converting enzyme (ACE) gene, c.3691+1G>A (IVS25+1G>A), causes a dramatic increase in circulating ACE through deletion of the transmembrane anchor.

Authors:  Alexandre Persu; Michel Lambert; Jaap Deinum; Marta Cossu; Nathalie de Visscher; Leonid Irenge; Jerôme Ambroise; Jean-Marc Minon; Andrew B Nesterovitch; Alexander Churbanov; Isolda A Popova; Sergei M Danilov; A H Jan Danser; Jean-Luc Gala
Journal:  PLoS One       Date:  2013-04-01       Impact factor: 3.240

10.  An angiotensin I-converting enzyme mutation (Y465D) causes a dramatic increase in blood ACE via accelerated ACE shedding.

Authors:  Sergei M Danilov; Kerry Gordon; Andrew B Nesterovitch; Heinrich Lünsdorf; Zhenlong Chen; Maricela Castellon; Isolda A Popova; Sergey Kalinin; Emma Mendonca; Pavel A Petukhov; David E Schwartz; Richard D Minshall; Edward D Sturrock
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.